Key result
Increased cholesterol loading capacity is linked to ~155% higher odds of non-calcified plaque progression in RA.
Why the study?
Is change in serum cholesterol loading capacity associated with coronary atherosclerosis progression in patients with rheumatoid arthritis?
Cohort (n=100)
Is change in serum cholesterol loading capacity associated with coronary atherosclerosis progression in patients with rheumatoid arthritis?
Answers are grounded in this paper and cite their sources.
Increases in serum cholesterol loading capacity over time are associated with coronary atherosclerosis progression in patients with rheumatoid arthritis.
OBJECTIVE: Excess cholesterol loading on arterial macrophages is linked to foam cell formation, atherosclerosis and cardiovascular risk in rheumatoid arthritis (RA). However, the effect of changes in cholesterol loading on coronary plaque trajectory and the impact of RA therapies on this relationship are unknown. We investigated the association between variations in cholesterol loading capacity (CLC) over time and atherosclerosis progression. METHODS: In a prospective observational cohort study, coronary CT angiography evaluated atherosclerosis (non-calcified, partially calcified or fully calcified plaques and coronary artery calcium (CAC) score) in 100 patients with RA without cardiovascular disease at baseline and 6.9±0.4 years later. The presence of ≥5 plaques and lesions rendering >50% stenosis was considered an extensive and obstructive disease, respectively. Serum CLC was measured on human THP-1 monocyte-derived macrophages with a fluorometric assay. RESULTS: Mean CLC change (follow-up CLC-baseline CLC) was 1.54 (SD 3.69) μg cholesterol/mg protein. In models adjusting for atherosclerotic cardiovascular disease risk score, baseline plaque and other relevant covariates, CLC change (per SD unit increase) is associated with a higher likelihood of progression of non-calcified (OR 2.55, 95% CI 1.22 to 5.35), fully calcified plaque (OR 3.10, 95% CI 1.67 to 5.76), CAC (OR 1.80, 95% CI 1.18 to 2.74) and new extensive or obstructive disease (OR 2.43, 95% CI 1.11 to 5.34). Exposure to prednisone unfavourably influenced, while biologics and statins favourably affected the relationship between CLC change and atherosclerosis progression (all p-for-interactions ≤0.048). CONCLUSION: CLC change is associated with atherosclerosis progression in a dose-dependent manner, including lipid-rich non-calcified plaques and extensive or obstructive disease that yield the greatest cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Karpouzas et al. (2024) conducted a cohort in Rheumatoid arthritis (n=100). Cholesterol loading capacity (CLC) change vs. Lower CLC change (per SD unit increase) was evaluated on Progression of non-calcified plaque (OR 2.55, 95% CI 1.22 to 5.35). An increase in cholesterol loading capacity over 6.9 years was associated with progression of non-calcified plaque and fully calcified plaque in patients with RA.
Synapse has enriched 10 related papers. Consider them for comparative context: